Viewing Study NCT03558503

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:41 PM
Ignite Modification Date: 2026-03-01 @ 10:08 AM
Study NCT ID: NCT03558503
Status: COMPLETED
Last Update Posted: 2022-09-16
First Post: 2018-05-08
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
Sponsor: UroGen Pharma Ltd.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Bladder Cancer View
None Urothelial Carcinoma View
None Urothelial Carcinoma Bladder View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Non-muscle invasive bladder cancer View
None Low grade non-muscle invasive bladder cancer View
None Intermediate risk non-muscle invasive bladder cancer View
None NMIBC View
None UGN-102 View
None Mitomycin View